Navitoclax (ABT-263)

Catalog No.S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Cited by 37 Publications

Nature, 2016, 538(7626):477-482

PubMed: 27760111

Blood, 2013, 121(10):1850-7

PubMed: 23303820

Blood, 2013, 122(9):1587-98

PubMed: 23881917

Blood, 2011, 117(26):7145-54

PubMed: 21562047

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651

Chem Sci, 2014, 5, 2794–2803

PubMed:

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046
Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075

Cell Death Dis, 2013, 4:e883

PubMed: 24157877

Cell Death Dis, 2013, 4:e742

PubMed: 23887633

Cell Death Dis, 2012, 3:e351

PubMed: 22825469

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506
Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126

Open Biol, 2015, 5(3)

PubMed: 25761368

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320

PLoS One, 2011, 6(9):e24590

PubMed: 21931768

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278

Microvasc Res, 2015, 101:72-81

PubMed: 26122935
Helsinki Metropolia University, 2013, Jens Desloovere

PubMed:

13 Customer Reviews

KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.
ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.
Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.
Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.
PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.
Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

(A) In vitro generated Mcl-1-deleted Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM. p185+ Arf-/- cells serve as a control. (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or (E) IM or (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

Navitoclax (ABT-263) purchased from Selleck.
Human Ph+ cell lines: (A) OP-1 Ph+ B-ALL (B) TOM1 Ph+ B-ALL and (C) BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL. For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Lr[2lEPTB;MD6wNFY3QSEQvF2=	NHXLPVRUSU6JRWK=
MV-4-11	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMEG1PFYh\|ryP	NV\peWZPW0GQR1XS
NKM-1	MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TvUGlEPTB;MD6wNVY6QSEQvF2=	MUXTRW5ITVJ?
ML-2	MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEG5PFMh\|ryP	MULTRW5ITVJ?
BV-173	MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjre4xKSzVyPUCuNFI{OTRizszN	MmnhV2FPT0WU
RS4-11	NXrWTI1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvrdWlyUUN3ME2wMlAzPTh5IN88US=>	MWjTRW5ITVJ?
HL-60	NUG2N\|F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL3eYtlUUN3ME2wMlAzQTB6IN88US=>	NUHEfFAxW0GQR1XS
KY821	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMEK5O\|Uh\|ryP	NHrvU\|RUSU6JRWK=
ECC10	M{W5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTNTWM2OD1yLkCzO\|kzKM7:TR?=	NXT1b4ZlW0GQR1XS
NCI-H720	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHaO284UUN3ME2wMlA1ODFzIN88US=>	NGDIU3BUSU6JRWK=
QIMR-WIL	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX2wXGE4UUN3ME2wMlA1Ojh5IN88US=>	Mn;tV2FPT0WU
KG-1	NVzBVHB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\nUYQ5UUN3ME2wMlA1PDh4IN88US=>	MW\TRW5ITVJ?
TGW	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfNTWM2OD1yLkC0OlM{KM7:TR?=	NIrMPYpUSU6JRWK=
ATN-1	MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMES3N\|Mh\|ryP	NF3vR3pUSU6JRWK=
RH-18	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml[zTWM2OD1yLkC2NFQ5KM7:TR?=	NUTKeYoxW0GQR1XS
EW-18	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{m5OGlEPTB;MD6wOlg1OSEQvF2=	M2rj[HNCVkeHUh?=
NB17	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMEexNlQh\|ryP	NX3r[mlvW0GQR1XS
SK-NEP-1	NInYRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLLNYJ1UUN3ME2wMlA4OjF\|IN88US=>	M3z1XHNCVkeHUh?=
P12-ICHIKAWA	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMEe3O\|gh\|ryP	NGnsVZdUSU6JRWK=
KARPAS-45	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjhR4xnUUN3ME2wMlA4QDF3IN88US=>	MU\TRW5ITVJ?
EW-3	NWW0WlQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXz0cXBbUUN3ME2wMlA5ODV\|IN88US=>	M3LnU3NCVkeHUh?=
NB13	M4XveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEiyNFMh\|ryP	MXLTRW5ITVJ?
NCI-H209	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMEi3NFQh\|ryP	MlHhV2FPT0WU
NCI-H1092	NGezTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2qzNWlEPTB;MD6xNFI4PSEQvF2=	NFXrR2lUSU6JRWK=
NH-12	M2jJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LX[mlEPTB;MD6xNFc1PCEQvF2=	MULTRW5ITVJ?
697	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jTeGlEPTB;MD6xNFg{QSEQvF2=	MULTRW5ITVJ?
KE-37	NHvsdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HBSmlEPTB;MD6xNVM4KM7:TR?=	MXjTRW5ITVJ?
MOLT-4	NUTielJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnvTWM2OD1yLkG1NVY6KM7:TR?=	NXfKSYFpW0GQR1XS
CHP-134	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2[4eGlEPTB;MD6xOlMxPiEQvF2=	M4L6W3NCVkeHUh?=
D-283MED	NIHMNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTVVGxSUUN3ME2wMlE4Pjh4IN88US=>	NXTkcZgyW0GQR1XS
LU-135	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMUi1OVIh\|ryP	MnzGV2FPT0WU
LU-134-A	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMUi2O\|Eh\|ryP	MnrTV2FPT0WU
EM-2	MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfrTZRKSzVyPUCuNVk6OThizszN	MlO2V2FPT0WU
LU-139	NI[zVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHf0ZnRKSzVyPUCuNlA1QThizszN	NYe1TldOW0GQR1XS
ALL-PO	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG2d2RKSzVyPUCuNlE6QDhizszN	NUT1V253W0GQR1XS
NB12	NYPxSFZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMkOxNVUh\|ryP	M3HKTnNCVkeHUh?=
KP-N-YN	NVX2RXRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnZdJFtUUN3ME2wMlI{PTd\|IN88US=>	NVLVWHRIW0GQR1XS
BEN	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX2xOHNKUUN3ME2wMlI{QTZ6IN88US=>	MVrTRW5ITVJ?
HCC1569	MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4L1b2lEPTB;MD6yOVExPiEQvF2=	MXnTRW5ITVJ?
HuO9	NIHRNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;lVmlEPTB;MD6yOlcyPSEQvF2=	NXfKWI9vW0GQR1XS
WM-115	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrGTWM2OD1yLkK3O\|M5KM7:TR?=	MkDYV2FPT0WU
CCRF-CEM	NFPi[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHJTIFQUUN3ME2wMlM{PTJ7IN88US=>	MUjTRW5ITVJ?
IST-SL1	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:1R3VKSzVyPUCuN\|U{PDNizszN	MmHJV2FPT0WU
BE-13	NYjFR2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLoTWM2OD1yLkO2OFU6KM7:TR?=	NFfSeYRUSU6JRWK=
COR-L88	MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfJdmFVUUN3ME2wMlM3PTRizszN	Mn;0V2FPT0WU
DOHH-2	M{S3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvk[HBtUUN3ME2wMlQyODJ\|IN88US=>	MmrPV2FPT0WU
A704	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUO2WGZuUUN3ME2wMlQzPjdizszN	NWjJXph4W0GQR1XS
KNS-81-FD	NGD5O4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXn4cot6UUN3ME2wMlQ1ODF5IN88US=>	NHrvb49USU6JRWK=
RPMI-8226	NIHTc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmezTWM2OD1yLkS1OlUzKM7:TR?=	M2HUUHNCVkeHUh?=
TGBC24TKB	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzhXoZLUUN3ME2wMlQ2Pzd6IN88US=>	MYnTRW5ITVJ?
NCI-H1304	M4SzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwNE[xOVch\|ryP	NEjqRlZUSU6JRWK=
MOLT-13	NIHPbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W5WmlEPTB;MD60OlYyOyEQvF2=	NHjqcFJUSU6JRWK=
EW-22	NYP1VHN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwNE[2O\|Eh\|ryP	NWrk[21jW0GQR1XS
MS-1	NGfaRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorhTWM2OD1yLkS2PVM{KM7:TR?=	MlXQV2FPT0WU
RMG-I	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHIOm9KSzVyPUCuOFk1PjRizszN	NUKxbmQ1W0GQR1XS
NTERA-S-cl-D1	Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PaW2lEPTB;MD61NFAyQSEQvF2=	NVK0O3JoW0GQR1XS
NCI-H1048	NUf5OIZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwNUC5OVMh\|ryP	M33YTHNCVkeHUh?=
SW1417	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwNUW0N\|gh\|ryP	M2\H[HNCVkeHUh?=
DB	NYn6ZpB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwNUewPEDPxE1?	MWDTRW5ITVJ?
MEG-01	NXPSO2g2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHuTWM2OD1yLkW4N\|Ih\|ryP	NHTjWHVUSU6JRWK=
EW-13	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnPfZB7UUN3ME2wMlU5OzRzIN88US=>	MmTjV2FPT0WU
LAMA-84	NH\qS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlq1TWM2OD1yLkW5NlA4KM7:TR?=	NWC5bWI6W0GQR1XS
J-RT3-T3-5	M1\vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwNkC4NFgh\|ryP	NYXrb5d1W0GQR1XS
MOLT-16	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwNkWyOlQh\|ryP	MmHDV2FPT0WU
DU-4475	NH3GbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVKzR3RlUUN3ME2wMlY2PDJ5IN88US=>	NV7uXY1mW0GQR1XS
HAL-01	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\3[oxKSzVyPUCuO\|I2PDlizszN	Mnu0V2FPT0WU
RD	M2XyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwN{W4PVkh\|ryP	MXrTRW5ITVJ?
OAW-28	NXLNOmJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXVTWM2OD1yLke4N\|ch\|ryP	NUPBd4FGW0GQR1XS
HCC38	M4fTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjyZ\|V5UUN3ME2wMlgxOTlizszN	Mki4V2FPT0WU
NMC-G1	M4PHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjjTWM2OD1yLkixNVIyKM7:TR?=	NVrtZZNrW0GQR1XS
EW-16	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj6N45PUUN3ME2wMlgyOzJ6IN88US=>	NGnTfnpUSU6JRWK=
DU-145	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXZUIk1UUN3ME2wMlg6QTJ\|IN88US=>	MnzFV2FPT0WU
HPAF-II	MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnvW3Y1UUN3ME2wMlkzPjJ6IN88US=>	MWHTRW5ITVJ?
A427	NEfi[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwOUOwNlIh\|ryP	MnHPV2FPT0WU
PA-1	NHru[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrxempKSzVyPUCuPVU3PDJizszN	NILlcFVUSU6JRWK=
OAW-42	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwOU[xOFYh\|ryP	MUfTRW5ITVJ?
L-428	NVj5V3JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIGxXFZKSzVyPUGuNFEzPSEQvF2=	NUHHO3dsW0GQR1XS
COLO-824	NWrhSpdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfJcpRpUUN3ME2xMlAyPzB6IN88US=>	NHXCRZNUSU6JRWK=
P30-OHK	M33jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTFwMES2PFgh\|ryP	NHXLZlBUSU6JRWK=
NCI-H2170	M2TC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELPVmRKSzVyPUGuNFYzOyEQvF2=	MV7TRW5ITVJ?
HCC2998	M4HJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTrTWM2OD1zLkC3NVM2KM7:TR?=	M1;idnNCVkeHUh?=
NB14	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjmN\|Y3UUN3ME2xMlE{PzR6IN88US=>	MmfEV2FPT0WU
TGBC1TKB	MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfkTWM2OD1zLkG0NVUzKM7:TR?=	MWrTRW5ITVJ?
KP-N-YS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUm4fVQzUUN3ME2xMlE3OjN4IN88US=>	M{fDZ3NCVkeHUh?=
CAL-120	NVvSSVBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDJTGxNUUN3ME2xMlE3PDJ7IN88US=>	MlfzV2FPT0WU
SBC-1	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTFwMUmwOVMh\|ryP	MYfTRW5ITVJ?
C32	MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlexTWM2OD1zLkG5NFg5KM7:TR?=	NEjjbVJUSU6JRWK=
HCC2157	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjmVlRMUUN3ME2xMlE6PDl2IN88US=>	M1vKNHNCVkeHUh?=
COLO-792	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi3WGVKSzVyPUGuNlAxPzFizszN	MlTsV2FPT0WU
ES7	NFHH[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPHS45KSzVyPUGuNlc6PTFizszN	NVfQVJY4W0GQR1XS
HEL	NHL4[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzUW5pxUUN3ME2xMlMyODJ7IN88US=>	Mn71V2FPT0WU
ES4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXCN\|FiUUN3ME2xMlM1QTl6IN88US=>	M3G5THNCVkeHUh?=
NCI-SNU-1	M4Tqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIX4V4FKSzVyPUGuN\|Y2PTVizszN	NHfHfIlUSU6JRWK=
MDA-MB-415	NVjZU2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fIb2lEPTB;MT6zPFg2KM7:TR?=	MnexV2FPT0WU
NCI-H2342	NE\FUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\1VFhmUUN3ME2xMlQxOjZ7IN88US=>	MomxV2FPT0WU
NB69	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fqNGlEPTB;MT60OlI4OSEQvF2=	M2\adHNCVkeHUh?=
D-247MG	NHPB[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XNOGlEPTB;MT61NVEzOiEQvF2=	MUfTRW5ITVJ?
SCC-4	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zWOmlEPTB;MT61PVg5PyEQvF2=	M3nyRXNCVkeHUh?=
HuH-7	M4HSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPXTWM2OD1zLk[3Nlk{KM7:TR?=	MX;TRW5ITVJ?
A388	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7CRXVKSzVyPUGuOlg4OjRizszN	Mmn5V2FPT0WU
Calu-3	NVHXc5JJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPSSFBKSzVyPUGuO\|A3QTdizszN	MUDTRW5ITVJ?
NCI-H1648	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXlSFdKSzVyPUGuO\|E1OThizszN	M37Kd3NCVkeHUh?=
NCI-H2052	NInucmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zhW2lEPTB;MT63NlIxOSEQvF2=	MWnTRW5ITVJ?
Ramos-2G6-4C10	M3\YR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjtTWM2OD1zLkezOlU3KM7:TR?=	M{PqfHNCVkeHUh?=
DEL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTFwN{S2PVIh\|ryP	M{LuNXNCVkeHUh?=
SNU-423	NITFcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXpTWM2OD1zLke4NVU4KM7:TR?=	NFPFS\|VUSU6JRWK=
COR-L23	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HZR2lEPTB;MT63PVg4PCEQvF2=	MX3TRW5ITVJ?
OMC-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XGNWlEPTB;MT64OlAyPiEQvF2=	Mlq2V2FPT0WU
EW-11	NVTKNGZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmX0TWM2OD1zLkm1OlU4KM7:TR?=	MXfTRW5ITVJ?
HSC-3	NFi1ZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fQZ2lEPTB;MT65OlM3PSEQvF2=	M2fwVXNCVkeHUh?=
MLMA	NF65eotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\KcXhKSzVyPUGuPVY3PzdizszN	NGHjT2hUSU6JRWK=
RCM-1	NHvsdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPYd5ZKSzVyPUKuNFA{QTlizszN	MVnTRW5ITVJ?
MFE-280	MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXziV3ZqUUN3ME2yMlAzQDR6IN88US=>	MXfTRW5ITVJ?
ES8	NH\1d\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHztSpJKSzVyPUKuNlU1PzFizszN	NULJPYVvW0GQR1XS
TE-11	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILQOoZKSzVyPUKuNlk1PzNizszN	NWq2RlFKW0GQR1XS
HuO-3N1	NU\qWJk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTJwNEi3PEDPxE1?	MY\TRW5ITVJ?
MHH-NB-11	NXHCRXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTJwNUGxOVgh\|ryP	MljkV2FPT0WU
TGBC11TKB	M3PVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nObmlEPTB;Mj61O\|Y5OSEQvF2=	MmX4V2FPT0WU
HOP-92	M1\tO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPMdFNKSzVyPUKuOVg4PDNizszN	NX\EXIwxW0GQR1XS
IGR-1	M3Hy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTJwNkKwN\|Uh\|ryP	MXLTRW5ITVJ?
GOTO	MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33icGlEPTB;Mj62OVM4PyEQvF2=	MVjTRW5ITVJ?
NCI-H1650	NYS5fWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGraPHFKSzVyPUKuO\|IzOTVizszN	NHXheY9USU6JRWK=
NCI-H1581	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTGT\|BKSzVyPUKuO\|k3QDFizszN	NF3mVnlUSU6JRWK=
NCI-H2405	M{LITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\uOIZuUUN3ME2yMlgzPzh{IN88US=>	MmLhV2FPT0WU
U-118-MG	NEXv[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjWVZdKSzVyPUKuPVY1QTFizszN	NV7QNWtsW0GQR1XS
DoTc2-4510	M4q5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Lhc2lEPTB;Mz6wNVQyPyEQvF2=	MUXTRW5ITVJ?
NCI-H596	NWXyWpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\qTWM2OD1\|LkC0PVk4KM7:TR?=	NFrjOYVUSU6JRWK=
MPP-89	M2rvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PjeGlEPTB;Mz6wOVY3PiEQvF2=	NV;CXGZYW0GQR1XS
GCIY	NWH2dZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTNwMkC0PVEh\|ryP	NWPadJdlW0GQR1XS
SW626	M{nT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvLTWM2OD1\|LkK0OVQ{KM7:TR?=	NGfJNFFUSU6JRWK=
OCI-AML2	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M172[mlEPTB;Mz6zNVI4OiEQvF2=	NFXPc3lUSU6JRWK=
NBsusSR	M3H4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fs[2lEPTB;Mz6zOFk{QCEQvF2=	MX7TRW5ITVJ?
AN3-CA	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1[x[GlEPTB;Mz60OFI{QCEQvF2=	MkHGV2FPT0WU
EFM-19	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Lz[GlEPTB;Mz60PFM{QSEQvF2=	NVTYRnk3W0GQR1XS
RVH-421	NYXpVlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37zOmlEPTB;Mz61Olg4PyEQvF2=	MX;TRW5ITVJ?
5637	MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnENpFXUUN3ME2zMlYyOTB\|IN88US=>	M13uZnNCVkeHUh?=
PANC-08-13	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWf0eosyUUN3ME2zMlY{PDd{IN88US=>	MmfJV2FPT0WU
H9	NFHBVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTNwNkexOFQh\|ryP	M3rNcXNCVkeHUh?=
KARPAS-299	NFu4UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTNwNkezOlEh\|ryP	MkfaV2FPT0WU
TE-5	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2roTGlEPTB;Mz63NFcxQSEQvF2=	MVTTRW5ITVJ?
NOS-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHyTWM2OD1\|Lke5PFM1KM7:TR?=	NEHCV4lUSU6JRWK=
HH	MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTNwOEO4Olgh\|ryP	M3jsXnNCVkeHUh?=
769-P	M1yxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHlTWM2OD1\|Lki5OVEh\|ryP	NGCycpNUSU6JRWK=
CHP-212	MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mof3TWM2OD1\|LkmyOVQ6KM7:TR?=	M3PLd3NCVkeHUh?=
NCI-H82	M3jT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELSbpdKSzVyPUOuPVU6OzZizszN	M3\QVnNCVkeHUh?=
Mo-T	NHmxZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rSdWlEPTB;ND6wOFMyOiEQvF2=	MnnUV2FPT0WU
BB65-RCC	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4e5U2lEPTB;ND6wOFM6QSEQvF2=	NIDVTmlUSU6JRWK=
SW1990	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTRwMEW5NFgh\|ryP	NG\oTGxUSU6JRWK=
LK-2	NV3RNmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTRwMUGyPVMh\|ryP	MlTPV2FPT0WU
ES5	NYPSSHY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLmO4ZKSzVyPUSuNVM6QDVizszN	NFjyZ5JUSU6JRWK=
JVM-3	Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTRwMUiyNlIh\|ryP	MW\TRW5ITVJ?
RPMI-7951	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jPZ2lEPTB;ND6yNlQyOyEQvF2=	NWi1dHViW0GQR1XS
Calu-6	NXHDUWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\JTWM2OD12LkK3PFgyKM7:TR?=	NIW5WG1USU6JRWK=
LC-2-ad	NYXlXlR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XNPWlEPTB;ND6yPVU3QCEQvF2=	NFS1NINUSU6JRWK=
SW954	M4DHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTRwMkm2OkDPxE1?	NWP4[ZY2W0GQR1XS
H-EMC-SS	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3PdG1KSzVyPUSuN\|E5OzFizszN	MlPLV2FPT0WU
ES3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTRwM{W0OFEh\|ryP	NH23[VVUSU6JRWK=
no-11	NXXQUGw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTRwM{W1OVQh\|ryP	MVrTRW5ITVJ?
LAN-6	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTiR2ZKSzVyPUSuOFUyQDlizszN	MXTTRW5ITVJ?
FTC-133	M{nUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO3V5N3UUN3ME20MlU{QTVizszN	MV3TRW5ITVJ?
8505C	NHLOZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TMVWlEPTB;ND61OFI{KM7:TR?=	M1vhbXNCVkeHUh?=
SW620	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTRwNUewOVch\|ryP	M2PvUHNCVkeHUh?=
BCPAP	M3H4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjVbmt1UUN3ME20MlY{PDhzIN88US=>	MYDTRW5ITVJ?
SK-LU-1	NVP2VmRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTRwNk[wPFkh\|ryP	NHnSVppUSU6JRWK=
NCI-H1623	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzlTJBnUUN3ME20MlcxOjJ6IN88US=>	MXPTRW5ITVJ?
C2BBe1	M3H6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fLRmlEPTB;ND63OFAxQCEQvF2=	M4\kVnNCVkeHUh?=
GP5d	NEjPZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PvV2lEPTB;ND63PFM5QCEQvF2=	MknTV2FPT0WU
NB6	NW\EVWJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHqNVVKSzVyPUSuPFYzODRizszN	MnLMV2FPT0WU
MDA-MB-157	M1\P[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTRwOEi3OkDPxE1?	M1LJOHNCVkeHUh?=
UMC-11	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;ETWM2OD12Lki4PVY1KM7:TR?=	NVz2[\|JEW0GQR1XS
HCC1419	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTRwOUCwOlMh\|ryP	NGDyXmlUSU6JRWK=
NCI-H2029	NIfWdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTRwOUSxPFUh\|ryP	NHTHTIFUSU6JRWK=
LXF-289	NW\0UlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTVwMEO3NVkh\|ryP	MUPTRW5ITVJ?
KINGS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHCTWM2OD13LkC3O\|Q1KM7:TR?=	MlHaV2FPT0WU
HD-MY-Z	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;3NnhQUUN3ME21MlI{QTZ7IN88US=>	NYi4cnBVW0GQR1XS
ESS-1	Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\CTWM2OD13LkK1OVk4KM7:TR?=	MlXGV2FPT0WU
GI-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX3TWM2OD13LkK3PVI3KM7:TR?=	MnH0V2FPT0WU
RPMI-2650	M2f1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvkOXEzUUN3ME21MlM3OTZizszN	MkXGV2FPT0WU
IA-LM	Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljhTWM2OD13LkO5PFcyKM7:TR?=	MVzTRW5ITVJ?
KP-4	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{m5UGlEPTB;NT60OlM{PCEQvF2=	NF:yd\|VUSU6JRWK=
G-402	M3SxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mly0TWM2OD13LkWxPFY2KM7:TR?=	M3vPeXNCVkeHUh?=
OS-RC-2	M4XVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjsUmc6UUN3ME21MlUzPjB2IN88US=>	MVHTRW5ITVJ?
NCI-H1155	NH33TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7sXG5{UUN3ME21MlU1QTV3IN88US=>	MXTTRW5ITVJ?
OE19	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIL1XmRKSzVyPUWuOlg3OjRizszN	NUDiOZcxW0GQR1XS
U-2-OS	Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILHUWJKSzVyPUWuPFkxOTNizszN	MYnTRW5ITVJ?
SCC-15	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjsfJltUUN3ME21Mlk{PjZ{IN88US=>	MnLWV2FPT0WU
NCI-H630	NYTzbFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnmb5p6UUN3ME21Mlk6PDB2IN88US=>	MYrTRW5ITVJ?
PFSK-1	NVn5fVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrYS5BbUUN3ME22MlA2OjV7IN88US=>	MlnmV2FPT0WU
NCI-H1770	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTZwMkC4O\|Qh\|ryP	MYPTRW5ITVJ?
SK-MEL-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTZwNEK5NVUh\|ryP	NELGTFBUSU6JRWK=
LB1047-RCC	Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofrTWM2OD14LkS3OlI2KM7:TR?=	MoLoV2FPT0WU
NCI-H446	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTZwNkK5NlUh\|ryP	M3rz[XNCVkeHUh?=
SW780	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nUW2lEPTB;Nj63NFE5PSEQvF2=	NGfJW\|lUSU6JRWK=
NEC8	NX\STXpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHTb5QzUUN3ME22Mlc3PjNizszN	Mom1V2FPT0WU
NOMO-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHPbVVKSzVyPU[uO\|gyOTFizszN	NV7Y[HpPW0GQR1XS
COLO-668	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHMRYhRUUN3ME22Mlg1Ozh5IN88US=>	M3PNdHNCVkeHUh?=
MC116	M3HIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrEW4RKSzVyPU[uPVM5QTdizszN	MkTZV2FPT0WU
HCC1937	M{nzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTZwOUmyOVEh\|ryP	NEL0VYtUSU6JRWK=
NCI-N87	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;mUGlEPTB;Nz6xPVI6OyEQvF2=	MYnTRW5ITVJ?
COLO-320-HSR	NF7K[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLmclc4UUN3ME23MlIzPzN6IN88US=>	NUO1UJFSW0GQR1XS
HCC1806	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fXcWlEPTB;Nz6yOlA1PCEQvF2=	NH62eVlUSU6JRWK=
OVCAR-3	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTdwM{OwN\|gh\|ryP	M1LuW3NCVkeHUh?=
NUGC-3	NGTTcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\pVlRKSzVyPUeuN\|k3QTRizszN	NGXFbphUSU6JRWK=
SW1783	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHP[HFjUUN3ME23MlQ{OTd3IN88US=>	Mn7oV2FPT0WU
GCT	NUPnZo5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTdwNU[5NFYh\|ryP	NU\XS5dwW0GQR1XS
NCI-H2126	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTdwN{O2NlUh\|ryP	NYX2b5ZUW0GQR1XS
MEL-HO	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrITJRKSzVyPUeuO\|cxPTRizszN	MYLTRW5ITVJ?
CAPAN-1	M{DnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTdwN{ezOVch\|ryP	MWjTRW5ITVJ?
SW756	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfLcWp7UUN3ME23Mlc5OzN\|IN88US=>	MVTTRW5ITVJ?
SKG-IIIa	M3:4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXJTWM2OD15LkixPFkzKM7:TR?=	MXjTRW5ITVJ?
HCE-T	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTQUnRKSzVyPUeuPFc4QDNizszN	Mn7IV2FPT0WU
Ca-Ski	M3:3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3S2T2lEPTB;Nz65PVM5OyEQvF2=	MWnTRW5ITVJ?
COLO-684	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHKTWM2OD16LkCxPFE5KM7:TR?=	MkL2V2FPT0WU
KYSE-70	NYrIflR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX[5eXVDUUN3ME24MlA4PzJ7IN88US=>	NWTYfW56W0GQR1XS
TI-73	MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPxPJpPUUN3ME24MlI2QDVzIN88US=>	NIDTdlBUSU6JRWK=
BT-20	M1XB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\OfGlEPTB;OD6yOlA2OiEQvF2=	NFrrNXZUSU6JRWK=
MHH-ES-1	NFO2[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXXe2JtUUN3ME24MlUyQDN2IN88US=>	NEfacIZUSU6JRWK=
TE-12	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRThwNUm5N\|Eh\|ryP	NVvuNFd3W0GQR1XS
YH-13	M3q1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\MbGlEPTB;OD62NVAxQCEQvF2=	MnjmV2FPT0WU
SF126	M1Pn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRThwOEO4OlUh\|ryP	M2nrSnNCVkeHUh?=
J82	M4nG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDORppiUUN3ME24MlkxODN6IN88US=>	MkPFV2FPT0WU
RCC10RGB	M{jNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRThwOUm1OlEh\|ryP	NGDTd\|JUSU6JRWK=
SK-UT-1	NUfNPZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\x[GlEPTB;OT6wOFk1PSEQvF2=	NW\qbI84W0GQR1XS
LB2241-RCC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3O0eWlEPTB;OT6xPVE{PyEQvF2=	MoPnV2FPT0WU
LB996-RCC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jWOmlEPTB;OT6xPVg6KM7:TR?=	MnewV2FPT0WU
EPLC-272H	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXsNYpKSzVyPUmuN\|c3PTdizszN	NHfTfmFUSU6JRWK=
CTV-1	NXG4WlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\xTWM2OD17LkW2OVMzKM7:TR?=	NHHtbZZUSU6JRWK=
HSC-2	NXTVOVRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILL[2hKSzVyPUmuOVc2PSEQvF2=	M2P3b3NCVkeHUh?=
SK-MEL-28	NFPMPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX74cpc6UUN3ME25MlYyQDl\|IN88US=>	M1n2fnNCVkeHUh?=
MMAC-SF	NFLFXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTlwNki3OUDPxE1?	MYrTRW5ITVJ?
CP50-MEL-B	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTlwN{W3PFIh\|ryP	M3vtfnNCVkeHUh?=
HT-1080	M363TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW0Um5KSzVyPUmuO\|c4OzlizszN	NVH5[XY4W0GQR1XS
HEC-1	M1W0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTFyLkOzOVIh\|ryP	MnuxV2FPT0WU
AGS	M4XESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPXTWM2OD1zMD6zO\|Qh\|ryP	M1PrTHNCVkeHUh?=
GAMG	NVfrfHVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XRTGlEPTB;MUCuOVE3OiEQvF2=	NInx[XVUSU6JRWK=
SW48	NXn6cJhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S3cmlEPTB;MUCuOVE5QSEQvF2=	M{jZOHNCVkeHUh?=
U031	M3rUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljSTWM2OD1zMD61PVA5KM7:TR?=	NX6xSmFqW0GQR1XS
OVCAR-5	NHryeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfje3VKSzVyPUGwMlY1OjlizszN	M163e3NCVkeHUh?=
SF295	NGf0R3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmryTWM2OD1zMD62O\|A1KM7:TR?=	MVrTRW5ITVJ?
BHT-101	NW\3[FR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjHeo9KSzVyPUGwMlcyPzdizszN	NGT0VJBUSU6JRWK=
VMRC-RCZ	NU\LenFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37yVWlEPTB;MUGuN\|IxOSEQvF2=	NVK2VWM6W0GQR1XS
ACHN	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;TUGNxUUN3ME2xNU41OjFzIN88US=>	MWLTRW5ITVJ?
NCI-H526	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTFzLkWwOFMh\|ryP	M4\CXHNCVkeHUh?=
MN-60	MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLyTWM2OD1zMT61N\|kh\|ryP	MkLoV2FPT0WU
NCI-H2291	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\BTmlEPTB;MUGuOVQ3PiEQvF2=	MVTTRW5ITVJ?
SCC-25	NELJT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzwPYhoUUN3ME2xNU44PTV4IN88US=>	Ml[wV2FPT0WU
SK-MEL-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTFzLke2N\|ch\|ryP	NXTmTpFnW0GQR1XS
SN12C	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHf1ZXZKSzVyPUGxMlk{PTVizszN	NF:1S\|VUSU6JRWK=
NCI-H69	NWXEWG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;hTGlEPTB;MUKuOFI{PCEQvF2=	NXnweoRFW0GQR1XS
ME-180	NWroSm5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTZTWM2OD1zMj63NFU1KM7:TR?=	Mn3ZV2FPT0WU
MC-IXC	M1jwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vYZmlEPTB;MUKuO\|UyQCEQvF2=	NXjLRldqW0GQR1XS
NCI-H2347	NX7tTlIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTF{Lke2NVQh\|ryP	NUHKNlBOW0GQR1XS
M059J	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTF{Lke3Nlch\|ryP	NXHNUlRkW0GQR1XS
A2058	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfvbmtFUUN3ME2xNk45PjhzIN88US=>	M3joeHNCVkeHUh?=
VA-ES-BJ	NWG0VHBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTF{Lki3PFUh\|ryP	NGfSWYxUSU6JRWK=
Ca9-22	NWXUeHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTF{Lkm0OVEh\|ryP	M4XIXXNCVkeHUh?=
KNS-42	NFPGTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTF{Lkm5PFQh\|ryP	MXLTRW5ITVJ?
LoVo	NUniZpZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfQeXdbUUN3ME2xN{4zOzF\|IN88US=>	MlvMV2FPT0WU
AM-38	NWO1fIV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjGTHdsUUN3ME2xN{4zPTZ4IN88US=>	MoHuV2FPT0WU
NB5	NHvob\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXyO\|JkUUN3ME2xN{4{PzV{IN88US=>	Ml;0V2FPT0WU
L-363	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmC1TWM2OD1zMz60NFM{KM7:TR?=	MX;TRW5ITVJ?
SK-MEL-30	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHu1OGFKSzVyPUG0MlA3PDVizszN	NXTIT3lRW0GQR1XS
NCI-H1563	NEfKN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LucmlEPTB;MUSuOlA{QSEQvF2=	MYrTRW5ITVJ?
NCI-H2228	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTF2Lk[wO\|ch\|ryP	M33UcHNCVkeHUh?=
MFM-223	NFj5V41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTaTWM2OD1zNT6xPFE{KM7:TR?=	M4D0VXNCVkeHUh?=
LB831-BLC	NYfTepl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYO2dGJXUUN3ME2xOU4zPzZ5IN88US=>	MoXzV2FPT0WU
SW872	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DYemlEPTB;MUWuN\|A5PiEQvF2=	Ml3HV2FPT0WU
NCI-H522	M2rjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTF3LkOzNFYh\|ryP	NV;jWXNrW0GQR1XS
EW-1	NIPLWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PMWmlEPTB;MUWuOVQ3OiEQvF2=	M4\ISXNCVkeHUh?=
HN	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2naOWlEPTB;MUWuOVk1OiEQvF2=	MWTTRW5ITVJ?
SW837	NUfUWWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTF3Lke4OFch\|ryP	NILPSXdUSU6JRWK=
SCC-9	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXsTIZKSzVyPUG1MlgyOTRizszN	NWrKUmRsW0GQR1XS
MKN7	NXXNe\|BYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXRVHJMUUN3ME2xOU46PzN{IN88US=>	M4nYO3NCVkeHUh?=
KYSE-410	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvJRm5uUUN3ME2xOk42QTFizszN	MmXYV2FPT0WU
SK-N-DZ	NE[5XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP4OnVKSzVyPUG2MlYyOTZizszN	M{jvcnNCVkeHUh?=
COR-L105	NH;2T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTF4Lk[1Nlgh\|ryP	NXvreIVuW0GQR1XS
LB2518-MEL	NWe5RlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3LTWM2OD1zNj64N\|g6KM7:TR?=	M{Kwd3NCVkeHUh?=
OVCAR-4	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkS1TWM2OD1zNj64PFYzKM7:TR?=	MmXHV2FPT0WU
TK10	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTF4Lkm0O\|Mh\|ryP	MY\TRW5ITVJ?
KNS-62	NIP3[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TiZmlEPTB;MU[uPVc4PyEQvF2=	MmDOV2FPT0WU
RPMI-8866	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjFfZJKSzVyPUG3MlE4OzJizszN	NH7Wc5BUSU6JRWK=
HuP-T4	NXHrXXNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonUTWM2OD1zNz6yOFk2KM7:TR?=	NFzEPYhUSU6JRWK=
CGTH-W-1	NYPkSZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofnTWM2OD1zNz61NlE6KM7:TR?=	NWjMR5ZCW0GQR1XS
T-24	M2XXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTF5LkWzOFch\|ryP	MUDTRW5ITVJ?
HT-3	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzlcZJNUUN3ME2xO{42QTF2IN88US=>	NVXJZ\|dYW0GQR1XS
KS-1	NH\ldJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPOW3ltUUN3ME2xO{43PzNizszN	MWrTRW5ITVJ?
NCI-H1792	M{T0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17UcWlEPTB;MUeuO\|k5KM7:TR?=	MVzTRW5ITVJ?
ABC-1	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHHVGpuUUN3ME2xO{45OTRzIN88US=>	NXzHeoxSW0GQR1XS
BPH-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrETWM2OD1zOD6xOlg2KM7:TR?=	M1;re3NCVkeHUh?=
A431	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M362emlEPTB;MUiuOFEzPyEQvF2=	MU\TRW5ITVJ?
T98G	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PH[GlEPTB;MUiuOVE2PyEQvF2=	MVfTRW5ITVJ?
BHY	NHrmTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTF6Lki2PUDPxE1?	M4raXHNCVkeHUh?=
Capan-2	NITZU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\JZY5KSzVyPUG4MlkxPzhizszN	NFL3ZVFUSU6JRWK=
MDA-MB-175-VII	NWH1RZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrtfpNSUUN3ME2xPE46OjB7IN88US=>	MmO3V2FPT0WU
CAL-27	M1nBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nHeGlEPTB;MUmuNFQ5PyEQvF2=	M2\ESnNCVkeHUh?=
AsPC-1	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTF7Lki2OVch\|ryP	MkDZV2FPT0WU
KU812	NEn0b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTTdW5KSzVyPUG5Mlk2PzNizszN	M3Ltc3NCVkeHUh?=
NCI-H441	NH;VZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEP4TW5KSzVyPUKwMlAxOSEQvF2=	Ml\hV2FPT0WU
Mewo	NHjIUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPobWg6UUN3ME2yNE4yOjh6IN88US=>	NVu4TlVYW0GQR1XS
SK-MEL-24	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTJyLkG0O\|ch\|ryP	MlvxV2FPT0WU
NCI-H727	NYrwN29NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjEN5FiUUN3ME2yNE4zPzB2IN88US=>	NVO2T2Q2W0GQR1XS
EKVX	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTJyLk[wOkDPxE1?	NFvweXVUSU6JRWK=
RT-112	M1vUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\lT2lEPTB;MkCuOlEzOiEQvF2=	MX3TRW5ITVJ?
CAMA-1	M361O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYexOYg3UUN3ME2yNE46QDB\|IN88US=>	MnX0V2FPT0WU
SW900	M4rJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\tc\|c1UUN3ME2yNU4xOTR7IN88US=>	MVnTRW5ITVJ?
NCI-H23	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVu2UFA4UUN3ME2yNU4yOjd5IN88US=>	M4L3VHNCVkeHUh?=
SK-PN-DW	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPHdmpUUUN3ME2yNU4yPjR7IN88US=>	NVvTRld3W0GQR1XS
BB30-HNC	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7ZTWM2OD1{MT6yO\|Q2KM7:TR?=	M2TkTXNCVkeHUh?=
VM-CUB-1	NWLhXldUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\IOHUxUUN3ME2yNU4{PTN4IN88US=>	NIjseXVUSU6JRWK=
IST-MEL1	NHXGZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXOze5JHUUN3ME2yNU4{Pjl{IN88US=>	MonhV2FPT0WU
CTB-1	NWSx[3J4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HnemlEPTB;MkGuOFc2PSEQvF2=	M2nVWHNCVkeHUh?=
LCLC-103H	NUfBWZd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zPOWlEPTB;MkKuNVU5OiEQvF2=	MXfTRW5ITVJ?
PANC-03-27	NHO4T2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJ{LkWxOlkh\|ryP	M1jsNXNCVkeHUh?=
HTC-C3	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfUOoZKSzVyPUKyMlU2PTVizszN	M4[2XHNCVkeHUh?=
TE-8	MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TPUmlEPTB;MkOuNlU3PSEQvF2=	NUm4RYJXW0GQR1XS
NCI-H292	NHLQcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFeyOGhKSzVyPUK1MlM2OzZizszN	NF3SSnZUSU6JRWK=
COLO-680N	NVnvXFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTJ3Lk[zNlkh\|ryP	NVzPZpJoW0GQR1XS
KYSE-520	NFX4TldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPPTWM2OD1{NT62OFQh\|ryP	NEnjbVNUSU6JRWK=
NB10	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXHTWM2OD1{Nj6zNVE4KM7:TR?=	NWXoN3ROW0GQR1XS
NCI-H661	NY\FV5J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTJ4LkS3NVMh\|ryP	Ml7wV2FPT0WU
GMS-10	M3jHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHWVGtlUUN3ME2yOk45PjN6IN88US=>	MYXTRW5ITVJ?
NCI-H2122	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnpZXVXUUN3ME2yOk46QTl6IN88US=>	MYfTRW5ITVJ?
OVCAR-8	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWX4SIpxUUN3ME2yO{4xPjN6IN88US=>	MUTTRW5ITVJ?
DJM-1	MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGm0TJpKSzVyPUK3MlE1PTRizszN	Mm[0V2FPT0WU
UACC-893	M1zQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHr2R3pKSzVyPUK3Mlk5PzhizszN	M3f5ZXNCVkeHUh?=
C8166	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fpcmlEPTB;MkiuOlk{QCEQvF2=	MnrsV2FPT0WU
NCI-H1693	NXO4fW12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\6SGlEPTB;MkiuOlk4PSEQvF2=	MUfTRW5ITVJ?
TYK-nu	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIS5OnBKSzVyPUOwMlA{PDVizszN	NFzSUJFUSU6JRWK=
SW1710	NYHJZndsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPVTWM2OD1\|MD6xNlYh\|ryP	MorsV2FPT0WU
A375	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTNyLkOyOFMh\|ryP	MoPUV2FPT0WU
HMV-II	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXsZ2NKSzVyPUOxMlM2QTJizszN	MXTTRW5ITVJ?
NCI-H2087	M3Psc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTNzLk[zOVIh\|ryP	MmSyV2FPT0WU
CAL-54	MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnXOJhRUUN3ME2zNU44OjRzIN88US=>	MVnTRW5ITVJ?
HCC70	NXe3fZZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILUbIlKSzVyPUOyMlE{QDdizszN	NHnTcmtUSU6JRWK=
ES1	NWG1UnlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M375ZmlEPTB;M{KuN\|A3OiEQvF2=	MUnTRW5ITVJ?
NCI-H1355	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPr[YRtUUN3ME2zN{4zODRizszN	Ml7EV2FPT0WU
CFPAC-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPy[ZFKSzVyPUOzMlI{OzJizszN	Mli0V2FPT0WU
MKN28	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTN\|LkO4NFkh\|ryP	MYjTRW5ITVJ?
HDLM-2	NWDiNlVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXtWnZSUUN3ME2zN{43QTNzIN88US=>	M2raV3NCVkeHUh?=
PANC-10-05	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrtS2hKSzVyPUO0MlExOTRizszN	M1[0T3NCVkeHUh?=
SAS	M{n3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHEZo1kUUN3ME2zOE41PTZ3IN88US=>	M{HIOHNCVkeHUh?=
HCC1395	NFXWVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\XOGVKSzVyPUO0MlcyQDZizszN	M{LaT3NCVkeHUh?=
8305C	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:5NmNKSzVyPUO1Mlg1OTVizszN	MWTTRW5ITVJ?
KM12	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\nWllsUUN3ME2zOk44PTR5IN88US=>	MWjTRW5ITVJ?
SW1116	M4\h[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37BNGlEPTB;M{euOVk6OiEQvF2=	NIfaU2pUSU6JRWK=
SK-MEL-1	M4rvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfI[oN{UUN3ME2zPE4{Ozh7IN88US=>	M2nmTXNCVkeHUh?=
HCC2218	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\jb3VKSzVyPUO4MlY2OTlizszN	MnvSV2FPT0WU
T84	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;4VWJ[UUN3ME2zPE44PDB7IN88US=>	M{fzbHNCVkeHUh?=
ETK-1	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG4TWM2OD1\|OT6wNlIh\|ryP	NF\oNnNUSU6JRWK=
COLO-800	NUf4S3JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHpSFJmUUN3ME2zPU4{QDZ6IN88US=>	M2mwOnNCVkeHUh?=
CAL-12T	MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTN7LkWyPFEh\|ryP	NFjtVIpUSU6JRWK=
ACN	NGrZTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYq4TGh{UUN3ME20NE41QTFzIN88US=>	MX;TRW5ITVJ?
SJSA-1	NXy4NXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYOw[GRjUUN3ME20NU4yPTl4IN88US=>	NUjTTG1EW0GQR1XS
PSN1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXBTWM2OD12MT6xO\|Q6KM7:TR?=	Mn\nV2FPT0WU
D-566MG	M2\jSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HmcWlEPTB;NEGuNlA5PiEQvF2=	MXrTRW5ITVJ?
EGI-1	M33hOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTR{LkSyPEDPxE1?	NVHQWHgxW0GQR1XS
A204	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTR{Lk[zPFgh\|ryP	NEXDXnRUSU6JRWK=
Saos-2	NXzPdHVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrybo9UUUN3ME20Nk45OzZ7IN88US=>	M2fUe3NCVkeHUh?=
SNU-C2B	NUDHXnVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV2xcGc4UUN3ME20N{43QDd6IN88US=>	MUjTRW5ITVJ?
HLE	NWfL[\|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\3NmlEPTB;NESuNFg2PiEQvF2=	NHW1clFUSU6JRWK=
SW1463	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\JV3RTUUN3ME20OE46QTdzIN88US=>	NXKweFI{W0GQR1XS
DSH1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3wTWM2OD12NT6wNFM{KM7:TR?=	MUfTRW5ITVJ?
MCF7	NF7n[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnrTo5KSzVyPUS1MlUxPTFizszN	MYnTRW5ITVJ?
K5	Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTR3Lkm0NFUh\|ryP	NWrve41iW0GQR1XS
NCI-H358	M4WxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTR5LkKxOUDPxE1?	MWTTRW5ITVJ?
NCI-H2030	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDnUnlKSzVyPUS3MlI{PzRizszN	NVqyT5hIW0GQR1XS
SW948	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDxTWM2OD12Nz60OlQh\|ryP	Ml;FV2FPT0WU
BALL-1	MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzYb\|NKSzVyPUS3MlYyPjhizszN	NIDIV4pUSU6JRWK=
TE-9	NWHVdo5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHy[IFKSzVyPUS3Mlk2QDFizszN	M2m4UHNCVkeHUh?=
SK-N-FI	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jySGlEPTB;NEiuNFM2QCEQvF2=	MVvTRW5ITVJ?
KALS-1	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4W2WmlEPTB;NEiuNVI5QSEQvF2=	MnjpV2FPT0WU
HO-1-N-1	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTR6Lke0OFUh\|ryP	NYTxRXNVW0GQR1XS
NCI-H2452	NIjLNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPyeoFbUUN3ME20PU4yOTV{IN88US=>	M37xc3NCVkeHUh?=
OC-314	NUDjVmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGn3OmRKSzVyPUS5MlY5OzRizszN	MUDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	+ Expand Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	+ Expand Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-15)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02143401	Recruiting	Cirrhosis\|Hepatitis B Infection\|Hepatitis C Infection\|Metastatic Malignant Solid Neoplasm\|Recurrent Hepatocellular Carcinoma\|Recurrent Malignant Solid Neoplasm\|Refractory Malignant Neoplasm\|Stage IV Hepatocellular Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 7 2014	Phase 1
NCT02079740	Recruiting	Advanced Malignant Solid Neoplasm\|KRAS Gene Mutation\|Metastatic Malignant Solid Neoplasm\|NRAS Gene Mutation\|Recurrent Colorectal Carcinoma\|Recurrent Lung Carcinoma\|Recurrent Malignant Solid Neoplasm\|Recurrent Pancreatic Carcinoma\|Stage III Colorectal Cancer AJCC v7\|Stage III Lung Cancer AJCC v7\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IIIA Colorectal Cancer AJCC v7\|Stage IIIB Colorectal Cancer AJCC v7\|Stage IIIC Colorectal Cancer AJCC v7\|Stage IV Colorectal Cancer AJCC v7\|Stage IV Lung Cancer AJCC v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Stage IVA Colorectal Cancer AJCC v7\|Stage IVB Colorectal Cancer AJCC v7\|Unresectable Malignant Neoplasm	National Cancer Institute (NCI)	March 7 2014	Phase 1\|Phase 2
NCT03222609	Recruiting	Myelofibrosis (MF)	AbbVie	October 31 2017	Phase 2
NCT02520778	Recruiting	EGFR Activating Mutation\|EGFR Exon 19 Deletion Mutation\|EGFR NP_005219.2:p.G719X\|EGFR NP_005219.2:p.L858R\|EGFR NP_005219.2:p.L861Q\|EGFR NP_005219.2:p.T790M\|Stage III Non-Small Cell Lung Cancer AJCC v7\|Stage IIIA Non-Small Cell Lung Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Non-Small Cell Lung Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT03366103	Recruiting	Metastatic Malignant Solid Neoplasm\|Recurrent Malignant Solid Neoplasm\|Recurrent Small Cell Lung Carcinoma\|Stage III Small Cell Lung Carcinoma AJCC v7\|Stage IIIA Small Cell Lung Carcinoma AJCC v7\|Stage IIIB Small Cell Lung Carcinoma AJCC v7\|Stage IV Small Cell Lung Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 29 2017	Phase 1\|Phase 2
NCT03181126	Recruiting	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 37 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-15)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 37 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-15)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)